Source:http://linkedlifedata.com/resource/pubmed/id/16824752
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
17
|
| pubmed:dateCreated |
2006-7-31
|
| pubmed:abstractText |
An initial investigation of the novel cyclopentane scaffold 6 afforded low nanomolar human NK1 antagonists having enhanced water solubility properties compared to morpholine 1. A synthesis of this cyclopentane scaffold, having three contiguous chiral centers, and the unexpected determination that the 1,2-trans-2,3-trans-ring stereochemistry, as opposed to the cis-ether/phenyl configuration of the known structures 1-5, is optimal for this class of antagonist are described.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0960-894X
|
| pubmed:author |
pubmed-author:CascieriMargaret AMA,
pubmed-author:ChicchiGary GGG,
pubmed-author:FinkePaul EPE,
pubmed-author:LevorseDorothy ADA,
pubmed-author:MaccossMalcolmM,
pubmed-author:MacintyreD EuanDE,
pubmed-author:MetzgerJoseph MJM,
pubmed-author:MeurerLaura CLC,
pubmed-author:MillsSander GSG,
pubmed-author:SadowskiSharonS,
pubmed-author:TsaoKwei-LanKL
|
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
16
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
4497-503
|
| pubmed:meshHeading | |
| pubmed:year |
2006
|
| pubmed:articleTitle |
Cyclopentane-based human NK1 antagonists. Part 1: discovery and initial SAR.
|
| pubmed:affiliation |
Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA. paul_finke@merck.com
|
| pubmed:publicationType |
Journal Article
|